Status:
COMPLETED
Retrospective Analysis of the Correlation Between Imaging Features and Pathology, Prognosis in Renal Tumors
Lead Sponsor:
Zhen Li
Conditions:
Radiomics
Deep Learning
Eligibility:
All Genders
Brief Summary
Renal cell carcinoma (RCC) is the most common malignant tumor in the kidney with a high mortality rate. Traditional imaging techniques are limited in capturing the internal heterogeneity of the tumor....
Detailed Description
Renal cell carcinoma (RCC) accounts for 80-90% of malignant tumors in the kidney and has the highest mortality rate among genitourinary tumors. Imaging examinations play an important role in the diagn...
Eligibility Criteria
Inclusion
- Our hospital admits patients with renal tumors in the urology department. The diagnosis is confirmed through surgical pathology, and the patients' imaging data is obtained through contrast-enhanced Computed Tomography or Magnetic Resonance examination in the radiology department.
Exclusion
- Patients who have undergone puncture, microwave, interventional therapies before the examination, or who have received chemotherapy or radiotherapy;
- Patients with poor respiratory coordination, resulting in significant image artifacts;
- Lesions are cystic, without discernible regions of interest, or with multiple regions of necrosis within the lesion;
- Lesions are too small, with a diameter of less than 1cm;
- Thin-slice imaging is not available in the CT scan.
Key Trial Info
Start Date :
August 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06167863
Start Date
August 31 2023
End Date
October 31 2023
Last Update
December 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhen Li
Wuhan, Hubei, China, 430030